Asklepion Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turnobi (L-citrulline intravenous) / Asklepion Pharma
NCT05253209: A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Terminated
3
64
US
L-citrulline, Plasmalyte A
Asklepion Pharmaceuticals, LLC
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
05/24
05/24
NCT06989567: A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Not yet recruiting
3
120
US
L-citrulline, Placebo
Asklepion Pharmaceuticals, LLC
Sickle Cell Disease
06/27
06/29
NCT04852172: L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

Terminated
1/2
30
US
L-citrulline, L-CIT, CIT, D5 1/2NS, Saline
Asklepion Pharmaceuticals, LLC
Acute Vaso Occlusive Crisis (VOC)
02/24
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turnobi (L-citrulline intravenous) / Asklepion Pharma
NCT05253209: A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Terminated
3
64
US
L-citrulline, Plasmalyte A
Asklepion Pharmaceuticals, LLC
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
05/24
05/24
NCT06989567: A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Not yet recruiting
3
120
US
L-citrulline, Placebo
Asklepion Pharmaceuticals, LLC
Sickle Cell Disease
06/27
06/29
NCT04852172: L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

Terminated
1/2
30
US
L-citrulline, L-CIT, CIT, D5 1/2NS, Saline
Asklepion Pharmaceuticals, LLC
Acute Vaso Occlusive Crisis (VOC)
02/24
02/24

Download Options